Introduction
============

Non-small cell lung cancer (NSCLC) is one of the most frequent and lethal malignancies worldwide; the 5-year survival rate is only 20% ([@b1-ol-0-0-8829]). Previous studies have indicated an increasing trend of NSCLC mortality in China in the previous 20 years, particularly in urban areas and among older (≥60 years old) people ([@b2-ol-0-0-8829],[@b3-ol-0-0-8829]). An increasing number of studies have demonstrated the emerging roles of long non-coding RNAs (lncRNAs) in the tumorigenesis of NSCLC and have suggested their potential clinical applications as diagnostic markers and therapeutic targets in NSCLC ([@b4-ol-0-0-8829],[@b5-ol-0-0-8829]).

LncRNAs are a class of non-coding RNAs that are \>200 nucleotides in length ([@b6-ol-0-0-8829]). Dysregulation of lncRNAs contributes to the development and progression of several human diseases, notably lung cancer ([@b7-ol-0-0-8829]). For example, Hox Transcript Antisense RNA promotes proliferation, survival, invasion, metastasis and drug resistance in lung cancer cells ([@b8-ol-0-0-8829]). Metastasis-associated lung adenocarcinoma transcript 1 is an important target for anti-metastatic therapy in NSCLC ([@b9-ol-0-0-8829],[@b10-ol-0-0-8829]). Antisense Noncoding RNA in the Inhibitors of cyclin dependent kinase 4 locus promotes NSCLC cell proliferation and inhibits apoptosis ([@b11-ol-0-0-8829]). Additional characterization of other lung cancer-associated lncRNAs will provide an improved understanding of their potential roles as therapeutic targets.

Ubiquitin-like with PHD and ring finger domains 1 (UHRF1) is overexpressed in various types of cancer, and was identified as a novel diagnostic marker of lung cancer ([@b12-ol-0-0-8829]). UHRF1, also known as ICBP90, was identified as a functional determinant of growth regulation genes, including p16^INK4A^ and p14^ARF^, and the expression of UHRF1 is only detectable in proliferating cells, not in quiescent cells ([@b13-ol-0-0-8829]). Previous studies identified that UHRF1 serves a central function in epigenetic modulation during DNA duplication in the S phase ([@b14-ol-0-0-8829]--[@b16-ol-0-0-8829]). Taniue *et al* ([@b17-ol-0-0-8829]) demonstrated that lncRNA UHRF1 protein associated transcript (UPAT) stabilizes the UHRF1 protein by interfering with its ubiquitination and degradation, and promotes colon tumorigenesis ([@b17-ol-0-0-8829]).

The present study demonstrated that UPAT expression was also upregulated in NSCLC tissues. Additionally, UPAT significantly promoted cell growth and G1-S phase transition of NSCLC cells. Furthermore, lncRNA UPAT suppressed the expressions of Ras association domain-containing protein 1 (RASSF1) and Cadherin-13 (CDH13) by increasing UHRF1 expression, thereby promoting NSCLC cell proliferation. In conclusion, the data of the present study suggested that the lncRNA UPAT promoted the proliferation of NSCLC cells and may be a potential therapeutic target of NSCLC.

Materials and methods
=====================

### Tissue collection and ethics statement

A total of 43 paired tumor tissues and matched normal tissues (\>2.0 cm distance from the tumor edge) were collected from patients with NSCLC (age range, 33--85 years old; mean age, 51.7 years old; 31 male and 12 female) who received surgical treatment between August 2011 and September 2015 at The Second Affiliated Hospital of Jiaxing University (Jiaxing, China). All experiments were approved by the Research Ethics Committee of Jiaxing University (Jiaxing, China). Written informed consent was obtained from all patients.

### Cell culture

The human lung epithelial BEAS-2B cell line and NSCLC H1299, H1650, H358 and A549 cell lines were purchased from Shanghai Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (Shanghai, China). The cells were cultured in RPMI-1640 medium (Life Technologies; Thermo Fisher Scientific, Inc., Waltham, MA, USA) containing 10% fetal bovine serum (Life Technologies; Thermo Fisher Scientific, Inc.), 100 IU/ml penicillin and 100 mg/ml streptomycin, and maintained at 37°C in humidified air containing 5% CO~2~.

### Reverse transcription quantitative polymerase chain reaction (RT-qPCR)

Total RNA of tissues and cells were extracted using of TRIzol reagent (Thermo Fisher Scientific, Inc.) according to the manufacturer\'s protocol. Total RNA was reverse transcribed to cDNA by using the PrimeScript RT Master Mix Kit (Takara Biotechnology Co., Ltd., Tokyo, Japan). qPCR was carried out using SYBR Green remix (Takara Biotechnology Co., Ltd.) using an ABI Step One instrument (Thermo Fisher Scientific, Inc.) with the following thermocycling conditions: 2 min at 94°C, followed by 40 cycles of 30 sec at 94°C, 30 sec at 60°C, 30 sec at 72°C, then 2 min at 72°C. The primers sequences were obtained from PrimerBank (<https://pga.mgh.harvard.edu/primerbank/>; date of access, November 15, 2011). The sequences were as follows: UPAT forward, AACCAAGAGCCTGAAGACG, reverse, CTCACCTCCTTTCTCACTCC; UHRF1 forward, GCCACCCAAAGTTCACATCTT and reverse, TGTTGCTATGACATTGCAGTCC; RASSF1 forward, CCCCGCAGTGCTATTGCAT and reverse, CACGAAGCGCACATTCTCTT; CDH13 forward, AGTGTTCCATATCAATCAGCCAG and reverse, CCTTACAGTCACTGAAGGTCAAG; GAPDH forward, TGTGGGCATCAATGGATTTGG and reverse, ACACCATGTATTCCGGGTCAAT. The relative amount of mRNA was calculated using the 2^−ΔΔCq^ method ([@b18-ol-0-0-8829]). Gene expression was normalized by GAPDH. All data were obtained from three individual experiments.

### Transfection of NSCLC cells

UPAT and UHRF1 siRNAs were purchased from Shanghai GenePharma Co., Ltd. (Shanghai, China). The siRNA sequence of UHRF1 was AAACAGAUGGAGGACGGCCA, and the siRNA sequence of UPAT was AGGAGGTGAGAGGGAATGT. A549 cells (1×10^5^ cells/well) were seeded in a 6-well culture plate containing complete medium 24 h prior to transfection. The negative control scramble or UPAT siRNA (50 pmol/well) or UHRF1 siRNA (50 pmol/well) were transfected with Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) in A549 cells according to the manufacturer\'s protocol. The full-length complementary DNA of UPAT was synthesized and subcloned into the pcDNA3 vector by Genewiz, Inc. (Suzhou, China), named pcDNA3-UPAT. The empty pcDNA3 vector (8 µg) or pcDNA3-UPAT (8 µg) were transfected with Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) in H1299 cells according to the manufacturer\'s protocol. At 24 h after transfection, the cells were treated and harvested.

### Western blotting

A549 and H1299 cells (1×10^7^) were lysed in radioimmunoprecipitation assay lysis buffer (Beyotime Institute of Biotechnology, Haimen, China) and protein concentrations were quantified using the BCA protein assay (Pierce; Thermo Fisher Scientific, Inc.). Equal quantities (20 µg) of protein were separated via SDS-PAGE (10%) and then transferred to polyvinylide fluoride membranes. The membranes were blocked with 5% skimmed milk in Tris-buffered saline with Tween-20 for 30 min at room temperature. This was followed by an incubation at 4°C overnight with primary antibodies: UHRF1 (sc-365392, 1:250 dilution; Santa Cruz Biotechnology, Inc., Dallas, TX, USA); RASSF1 (sc-18722, 1:200 dilution; Santa Cruz Biotechnology, Inc.); CDH13 (sc-166875, 1:300 dilution; Santa Cruz Biotechnology, Inc.); and GAPDH (sc-47724, 1:500 dilution; Santa Cruz Biotechnology, Inc.). The membranes were washed and then incubated with goat anti-mouse horseradish peroxidase-conjugated secondary antibody (sc-2005, 1:2,000 dilution; Santa Cruz Biotechnology, Inc.) at room temperature for 2 h. The membranes were then analyzed using ECL substrate (32106, Thermo Fisher Scientific, Inc.) following the manufacturer\'s protocol. GAPDH was used as an endogenous protein for normalization. Protein bands were quantified using the Tanon-5200 Image Analyzer (Shanghai, China). Quantification of blots using Image J software (NIH, USA).

### CCK-8 assay

The proliferation of A549 and H1299 cells were analyzed with a Cell Counting Kit-8 (CCK-8) (Dojindo Molecular Technologies, Kumamoto, Japan). A549 and H1299 cells (1×10^4^ cells/well) were seeded in 96-well plates at 37°C in humidified 5% CO~2~ atmosphere. Following transfection treatment, 10 µl CCK-8 solution was added into each well and then incubated for another 4 h at 37°C. CCK-8 reagent was added at 0, 24, 48 and 72 h according to the manufacturer\'s protocol. The absorbance at 450 nm was measured using a microplate reader.

### Cell cycle analysis

Following transfection treatment, A549 and H1299 cells were trypsinized and washed with cold PBS. The cells (1×10^6^) were fixed in pre-chilled 70% ethanol at −20°C overnight. For measurement of DNA content, cells were stained with propidium iodide solution (50 µg/ml propidium iodide, 100 µg/ml RNase A, 0.05% Triton X-100 in PBS), and incubated at 37°C in the dark for 30 min. DNA content analysis by flow cytometry with a FACSCalibur system (BD Biosciences, Franklin Lakes, NJ, USA). The percentage of the cell population in each phase was calculated with the FlowJo FACS analysis software (version 7.0; Tree Star, Inc., Ashland, OR, USA).

### Plasmid transfection and dual-luciferase reporter assay

The sequence of human UHRF1 (Gene ID: 29128) promoter (−2,000 bp) was obtained from the UCSC Genome Browser (uc002mbo.3, Human GRCh37/hg19; <http://genome.ucsc.edu/>; date of access, February 13, 2017) and purchased from Genewiz, Inc. (Suzhou, China). The sequence was cloned into the luciferase reporter vector pGL4 (Promega Corporation, Madison, WI, USA) to produce the pGL4-UHRF1 plasmid. The pGL4.74 vector was also purchased from Promega Corporation. The siRNA sequence of siRNA sequence of UPAT is AGGAGGTGAGAGGGAATGT. NSCLC A549 cells (1×10^5^) were seeded in a 6-well culture plate containing complete medium 24 h prior to transfection. The negative control scramble or UPAT siRNA (50 pmol/well) were transfected with Lipofectamine^®^ 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) in A549 cells according to the manufacturer\'s protocol. The empty pcDNA3 vector (8 µg) or pcDNA3-UPAT (8 µg) were transfected with Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) in A549 cells according to the manufacturer\'s protocol. After 24 h post-transfection, the A549 cells were transfected with pGL4-UHRF1 and pGL4.74 vectors using Lipofectamine^®^ 3000 according to manufacturer\'s protocol. Cells were cultured for 8 h after plasmid transfection. Then, the luciferase activity was measured using a Dual-Luciferase Reporter assay system (E1910; Promega Corporation) according to the manufacturer\'s protocol. Data were normalized to the activity of *Renilla* luciferase.

### Statistical analysis

Data are presented as mean ± standard deviation of three independent experiments. Differences between groups were analyzed by GraphPad Prism 5 software (GraphPad Software, Inc., La Jolla, CA, USA) with unpaired Student\'s t-test or one-way analysis of variance with a Tukey-Kramer post hoc test. The Pearson\'s Chi-square test was used to evaluate the difference between levels of UPAT expression in specimens and clinicopathological characteristics. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### UPAT is upregulated in human NSCLC tissues and cells

The expression of the UPAT in 43 human NSCLC tissues and matched adjacent normal tissues was first examined using RT-qPCR analysis. The results indicated that UPAT expression was significantly upregulated in NSCLC tissues compared with the control ([Fig. 1A](#f1-ol-0-0-8829){ref-type="fig"}). The expression of UPAT was also analyzed in normal human lung epithelial BEAS-2B cell line and NSCLC H1299, H1650, H358 and A549 cell lines; the UPAT level was significantly increased in NSCLC cells compared with its expression in the BEAS-2B cells. In addition, the UPAT level was significantly increased in the A549 cells (4.48-fold change) compared with its expression in the H1299 cells ([Fig. 1B](#f1-ol-0-0-8829){ref-type="fig"}). Furthermore, all samples from patients with NSCLC were divided into two groups, including a UPAT low-expression group (n=21) and a high-expression group (n=22). The median (2.13, in tumor group) was used as cut-off value. Then, the χ^2^ analysis was performed to explore the potential associations between UPAT expression and clinical characteristics; the data revealed that the expression level of UPAT was significantly associated with tumor size, Tumor-Node-Mestastasis stage and history of smoking, which suggests that the abnormal expression of UPAT contributed to the development of NSCLC ([Table I](#tI-ol-0-0-8829){ref-type="table"}).

### UPAT promotes NSCLC cell proliferation and inhibits G1 arrest in vitro

To explore the function of UPAT in NSCLC cells, the A549 and H1299 cell lines were selected for additional studies, as they exhibited the highest and lowest UPAT expression levels, respectively ([Fig. 1B](#f1-ol-0-0-8829){ref-type="fig"}). Then, the overexpression plasmid and siRNA were used for transfection into the H1299 and A549 cell lines, respectively. The qPCR analysis indicated that the level of UPAT was increased in H1299 cells with pcDNA3-UPAT transfection ([Fig. 2A](#f2-ol-0-0-8829){ref-type="fig"}). The level of UPAT was decreased in A549 cells with UPAT siRNA transfection ([Fig. 2B](#f2-ol-0-0-8829){ref-type="fig"}). Therefore, these 2 cell lines were used in all additional experiments for UPAT overexpression or silencing, respectively. To determine the effect of UPAT on NSCLC cell proliferation, a CCK-8 assay was performed. The results indicated that the cell proliferation of H1299 cells transfected with pCDNA-UPAT was significantly increased compared with the control groups ([Fig. 2C](#f2-ol-0-0-8829){ref-type="fig"}). By contrast, UPAT knockdown inhibited the A549 cell proliferation ([Fig. 2D](#f2-ol-0-0-8829){ref-type="fig"}). These data indicated that UPAT markedly promoted the proliferation of NSCLC cells. The effects of UPAT on the cell cycle were additionally investigated. As indicated in [Fig. 2E](#f2-ol-0-0-8829){ref-type="fig"}, overexpressing UPAT decreased the number of H1299 cells in the G1 phase and increased the number of cells in the S phase compared with the control. However, UPAT siRNA transfection caused a G1 phase cell-cycle arrest, with a significant increase in the percentage of A549 cells in G1 stage ([Fig. 2F](#f2-ol-0-0-8829){ref-type="fig"}). These results suggest that the proliferation-inducing effects of UPAT are probably attributable to the promotion of the G1-S phase transition.

### UPAT inhibits RASSF1 and CDH13 expression

A previous study demonstrated that UPAT is associated with UHRF1 and increases its protein level ([@b17-ol-0-0-8829]). Additionally, UHRF1 knockdown contributes to lower methylation levels of RASSF1 and CDH13 promoters in A549 NSCLC cells ([@b19-ol-0-0-8829]). To study the underlying molecular mechanisms and downstream targets involved in the effect of UPAT on cell cycle and growth, the mRNA levels of RASSF1 and CDH13, which are tumor suppressor genes involved in cell cycle and proliferation and are also inhibited by UHRF1 in NSCLC ([@b20-ol-0-0-8829],[@b21-ol-0-0-8829]), were examined. The qPCR analysis demonstrated that RASSF1 and CDH13 mRNA levels were decreased in H1299 cells transfected with pCDNA-UPAT compared with the control ([Fig. 3A](#f3-ol-0-0-8829){ref-type="fig"}). By contrast, UPAT knockdown increased the RASSF1 and CDH13 mRNA levels in A549 cells ([Fig. 3B](#f3-ol-0-0-8829){ref-type="fig"}). Similarly, RASSF1 and CDH13 protein levels were decreased in H1299 cells transfected with pCDNA-UPAT but increased in A549 cells transfected with UPAT siRNA compared with the respective controls ([Fig. 3C and D](#f3-ol-0-0-8829){ref-type="fig"}). Furthermore, it was also confirmed that UPAT overexpression increased the protein level of UHRF1 in the H1299 cells, but that UPAT knockdown decreased the protein level of UHRF1 in the A549 cells ([Fig. 3C and D](#f3-ol-0-0-8829){ref-type="fig"}). These results suggested that UPAT may promote NSCLC cell proliferation partly through epigenetic silencing of RASSF1 and CDH13 transcription.

### UHRF1 overexpression is potentially involved in the oncogenic function of UPAT

Luciferase vectors carrying the UHRF1 promoter (−2,000 bp) in front of the firefly luciferase gene coding region were constructed. As indicated in [Fig. 4A](#f4-ol-0-0-8829){ref-type="fig"}, pCDNA-UPAT significantly increased the luciferase activity of the UHRF1 promoter; concurrently, treatment with UPAT siRNA suppressed the luciferase activity of UHRF1 promoter. To validate whether UPAT regulated NSCLC cell proliferation by increasing UHRF1 expression, rescue experiments were performed. A549 cells were co-transfected with pcDNA-UPAT and UHRF1 siRNA ([Fig. 4B](#f4-ol-0-0-8829){ref-type="fig"}), and the CCK-8 and cell cycle assays results indicated that the knockdown of UHRF1 partially decreased the promotion of cell growth and G1-S phase transition resulting from UPAT overexpression ([Fig. 4C and D](#f4-ol-0-0-8829){ref-type="fig"}). These results indicated that the effects of UPAT on NSCLC cell proliferation partially depended on its effect of increasing UHRF1 levels.

Discussion
==========

UHRF1, which is overexpressed in several types of cancer, including breast, prostate and lung cancer, is a key regulator in the G1/S transition during the cell cycle ([@b22-ol-0-0-8829]). Previous studies have suggested that UHRF1/ICBP90 is associated with histone ubiquitination and DNA methylation in the context of tumor angiogenesis and silencing of tumor suppressor genes ([@b23-ol-0-0-8829]--[@b26-ol-0-0-8829]). UHRF1 binds hemi-methylated DNA through its SET- and RING-associated domain, triggering the recruitment of DNA (cystosine-5)-methyltransferase 1 and Histone deacetylase 1 ([@b27-ol-0-0-8829],[@b28-ol-0-0-8829]). UHRF1 also mediates tumor suppressor gene inactivation in NSCLC ([@b19-ol-0-0-8829]). UHRF1 knockdown contributes to lower methylation levels of RASSF1 and CDH13 promoters in A549 NSCLC cells ([@b19-ol-0-0-8829]). In the present study, it was identified that the expression of UPAT in NSCLC tissues was significantly increased compared with paratumor tissues, suggesting that UPAT serves a crucial role in NSCLC. Therefore, it was hypothesized that UPAT may exert its effects through increasing UHRF1 and epigenetically silencing RASSF1 and CDH13 transcription.

The data from the present study suggested that UPAT significantly promoted the proliferation of NSCLC cells by enhancing G1-S phase transition. Consistently, UPAT promotes colon tumorigenesis by inhibiting the degradation of UHRF1 ([@b17-ol-0-0-8829]). Additionally, in the present study, the downstream target genes of UHRF1 was analyzed by qPCR and western blotting assays, and the data indicated that RASSF1 and CDH13 were upregulated following UPAT knockdown. RASSF1 may form an endogenous complex with the activated Ras oncoprotein and integrate pro-growth pathways with pro-growth arrest/death pathways ([@b21-ol-0-0-8829],[@b29-ol-0-0-8829]). CDH13 mediates cell growth arrest and regulates the cyclin-dependent kinase inhibitor 1 pathway ([@b30-ol-0-0-8829]). Loss of expression and aberrant methylation of the RASSF1 and CDH13 is observed in lung cancer ([@b20-ol-0-0-8829],[@b31-ol-0-0-8829]). In the present study, it was demonstrated that RASSF1 and CDH13 served as tumor suppressors and were silenced by UPAT in NSCLC cells. Concurrently, UPAT also increased the expression of UHRF1.

To additionally confirm that UPAT exerted its effects through increasing UHRF1, recue experiments were performed and it was identified that the knockdown of UHRF1 partially diminished UPAT-promoted cell growth and G1-S phase transition. These results revealed that the effects of UPAT on NSCLC cell proliferation were partially dependent on increasing UHRF1 expression.

In conclusion, the present study provides evidence that UPAT is upregulated in NSCLC tissues. The role of UPAT in the promotion of NSCLC cell proliferation may function partly via epigenetically inhibiting RASSF1 and CDH13 transcription by stabilizing UHRF1 expression and increasing the UHRF1-mediated methylation modification of these target genes. UPAT may serve as a potential target for the diagnosis and treatment of human NSCLC.
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![Relative expression of UPAT in NSCLC tissues and cells. (A) The relative expression of UPAT in NSCLC tissues (n=43) compared with corresponding non-tumor tissues (n=43). UPAT expression was examined by qPCR and normalized to GAPDH expression. The results are presented as the median fold change in tumor tissues compared with normal tissues, with interquartile ranges. \*P\<0.05 by Student\'s t-test. (B) UPAT expression was assessed by qPCR in the normal human lung epithelial BEAS-2B cell line and NSCLC H1299, H1650, H358 and A549 cell lines. GAPDH was used as an internal control. Data are presented as mean ± standard deviation. n=3. \*P\<0.05 by analysis of variance. UPAT, Ubiquitin-like with PHD and RING finger domains 1 protein associated transcript; NSCLC, non-small cell lung cancer; qPCR, quantitative polymerase chain reaction.](ol-16-02-1491-g00){#f1-ol-0-0-8829}

![UPAT promotes NSCLC cell growth and G1-S phase transition. Quantitative polymerase chain reaction analysis of UPAT expression levels in H1299 cells transfected with (A) pcDNA-UPAT (OE) and (B) A549 cells transfected with UPAT siRNA (KD) or ctrl. GAPDH was used as an internal control. Data are presented as mean ± SD. n=3. \*P\<0.05 by Student\'s t-test. CCK-8 assays were performed to determine the proliferation of (C) H1299 cells transfected with pcDNA-UPAT (OE) and (D) A549 cells transfected with UPAT siRNA (KD) or ctrl. Data are presented as mean ± SD. n=3. \*P\<0.05 by Student\'s t-test. Cell cycle assays were performed to determine the cell cycle phase of (E) H1299 cells transfected with pcDNA-UPAT (OE) and (F) A549 cells transfected with UPAT siRNA (KD) or ctrl. GAPDH was used as an internal control. Data are presented as mean ± SD. n=3. \*P\<0.05 by Student\'s t-test. UPAT, Ubiquitin-like with PHD and RING finger domains 1 protein associated transcript; NSCLC, non-small cell lung cancer; OE, overexpressed; KD, knockdown; SD, standard deviation; si, small interfering; ctrl, control; OD, optical density.](ol-16-02-1491-g01){#f2-ol-0-0-8829}

![UPAT inhibits RASSF1 and CDH13 expression. (A and B) Quantitative polymerase chain reaction assays were used to examine the changes of RASSF1 and CDH13 mRNAs in (A) H1299 cells transfected with pcDNA-UPAT (OE) and (B) A549 cells transfected with UPAT siRNA (KD) or ctrl. GAPDH was used as an internal control. Data are presented as mean ± SD. n=3. \*P\<0.05 by Student\'s t-test. Western blotting analysis of UHRF1, RASSF1 and CDH13 protein levels in (C) H1299 cells transfected with pcDNA-UPAT (OE) and (D) A549 cells transfected with UPAT siRNA (KD) or ctrl. GAPDH was used as an internal control. Data are presented as mean ± SD. n=3. \*P\<0.05 by Student\'s t-test. UHRF1, Ubiquitin-like with PHD and RING finger domains 1; UPAT, UHRF1 protein associated transcript; OE, overexpressed; KD, knockdown; SD, standard deviation; si, small interfering; ctrl, control; RASSF1, Ras association domain-containing protein 1; CDH13, Cadherin-13.](ol-16-02-1491-g02){#f3-ol-0-0-8829}

![UHRF1 overexpression is potentially involved in the oncogenic function of UPAT. (A) A549 cells were transfected with pcDNA-UPAT (OE), UPAT siRNA (KD), or the negative control. After 24 h, cells were transfected with pGL4-UHRF1 promoter (−2,000 bp) luciferase vector and pGL4.74 plasmids for 12 h. The luciferase activity was determined using a dual-luciferase reporter assay system. Data are presented as mean ± SD. n=3. \*P\<0.05 by ANOVA. (B) Western blotting analysis of UHRF1 protein level in A549 cells treated with pcDNA-UPAT and UHRF1 siRNA, or the negative control. (C) CCK-8 assay was used to determine the cell viability for pcDNA-UPAT and UHRF1 siRNA co-transfected A549 cells. Data are presented as mean ± SD. n=3. \*P\<0.05 by ANOVA vs. Ctrl and OE/siUHRF1 groups. (D) Cell cycle assay was performed to determine the cell cycle phase of pcDNA-UPAT and UHRF1 siRNA co-transfected A549 cells. GAPDH was used as an internal control. Data are presented as mean ± SD. n=3. \*P\<0.05 by ANOVA. UHRF1, Ubiquitin-like with PHD and RING finger domains 1; UPAT, UHRF1 protein associated transcript; OE, overexpressed; KD, knockdown; SD, standard deviation; si, small interfering; ctrl, control; ANOVA, analysis of variance.](ol-16-02-1491-g03){#f4-ol-0-0-8829}

###### 

Association between UPAT expression and clinicopathological characteristics of patients with non-small cell lung cancer (n=43).

  Characteristics      All patients   UPAT low expression \[\< median\]^[a](#tfn1-ol-0-0-8829){ref-type="table-fn"}^(%)   UPAT high expression \[≥ median\]^[a](#tfn1-ol-0-0-8829){ref-type="table-fn"}^ (%)   P-value^[b](#tfn2-ol-0-0-8829){ref-type="table-fn"}^
  -------------------- -------------- ----------------------------------------------------------------------------------- ------------------------------------------------------------------------------------ ------------------------------------------------------
  Total                43             21 (48.8)                                                                           22 (51.2)                                                                            --
  Age, years                                                                                                                                                                                                   0.85
    \<60               26             13 (50.0)                                                                           13 (50.0)                                                                            --
    ≥60                17               8 (47.1)                                                                            9 (52.9)                                                                           --
  Sex                                                                                                                                                                                                          0.56
    Male               31             16 (51.6)                                                                           15 (48.4)                                                                            --
    Female             12               5 (41.7)                                                                            7 (58.3)                                                                           --
  Tumor size, cm                                                                                                                                                                                               0.01^[c](#tfn3-ol-0-0-8829){ref-type="table-fn"}^
    \<3                18             13 (72.2)                                                                             5 (27.8)                                                                           --
    ≥3                 25               8 (32.0)                                                                          17 (68.0)                                                                            --
  TNM stage                                                                                                                                                                                                    0.04^[c](#tfn3-ol-0-0-8829){ref-type="table-fn"}^
    I--II              24             15 (62.5)                                                                             9 (37.5)                                                                           --
    III--IV            19               6 (31.6)                                                                          13 (68.4)                                                                            --
  Metastasis                                                                                                                                                                                                   0.92
    No                 29             14 (48.3)                                                                           15 (51.7)                                                                            --
    Yes                14               7 (50.0)                                                                            7 (50.0)                                                                           --
  History of smoking                                                                                                                                                                                           0.03^[c](#tfn3-ol-0-0-8829){ref-type="table-fn"}^
    Never              12               9 (75.0)                                                                            3 (25.0)                                                                           --
    Ever               31             12 (38.7)                                                                           19 (61.3)                                                                            --

The median expression level of UPAT was used as the cut-off.

χ^2^test.

P\<0.05. UPAT, Ubiquitin-like with PHD and RING finger domains 1 protein associated transcript; TNM, tumor node metastasis.
